[Effect of using icodextrin as a starting therapy for peritoneal permeability]

Area of Science:

• Nephrology
• Biomaterials Science

Background:

• Peritoneal permeability varies among patients starting peritoneal dialysis (PD) and can increase over time.
• Factors influencing permeability include peritonitis, dialysis fluid biocompatibility, and glucose use.
• Understanding and managing peritoneal permeability is crucial for effective PD therapy.

Purpose of the Study:

• To investigate the effect of daily icodextrin use on peritoneal permeability evolution in PD patients.
• To compare icodextrin's impact on peritoneal transport with traditional glucose-based osmotic agents.

Main Methods:

• A study involving 56 patients initiating PD with one daily icodextrin exchange.
• Peritoneal transport kinetics, including creatinine (Cr-MTAC) and urea (U-MTAC) mass transfer coefficients and D/P creatinine, were assessed over two years.
• A control group of 249 patients using only glucose as an osmotic agent was used for comparison.

Main Results:

• Peritoneal transport (Cr-MTC, U-MTC, D/P Cr) decreased significantly within 12 months of starting icodextrin and remained stable.
• High transporters (HA) showed a greater reduction in Cr-MTAC during the first year.
• Icodextrin use resulted in a significantly higher reduction in Cr-MTAC compared to glucose (p<0.001).

Conclusions:

• Daily icodextrin use at PD initiation may help correct high peritoneal transport status.
• Peritoneal transport kinetic studies at 6 and 12 months are more indicative of long-term patient characteristics than baseline studies.